Eisai seeks Japanese PMDA approval for subcutaneous formulation of Leqembi to treat early Alzheimer’s disease: Tokyo Monday, December 1, 2025, 14:00 Hrs [IST] Eisai Co., Ltd. an ...

Prompt treatment following traumatic brain injury (TBI) lowers risk of developing Alzheimer's disease (AD) in subsequent ...

Researchers at Brain Chemistry Labs, a state-of-the-art biology laboratory in Jackson, are studying the brains of dolphins in ...

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the ...

Nanyang Technological University, Singapore (NTU Singapore) is leading 24 clinicians from the region and beyond to set up ...

The DOC's existing health care provider, VitalCore, will operate the new hotline, as prison officials respond to six apparent suicides this year — compared to zero in 2024.

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home ...

Nanyang Technological University, Singapore (NTU Singapore) is leading 24 clinicians from the region and beyond to set up Southeast Asia’s first ...

The Supreme Court will hear a public interest litigation (PIL) seeking directions to the Centre and all State Governments to frame statutory rules for prosecuting cases of ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that Eisai has completed the rolling submission of the Supplemental Biologics License Application (sBLA ...

Holding an allopathic doctor negligent for prescribing Ayurvedic Medicine, the District Consumer Disputes Redressal ...

New research shows that young adults with obesity already display biological patterns associated with liver stress, chronic inflammation, and early neural injury—changes typically seen in older adults ...